Personalized medicine is driving the need for isolation of rarer target cell populations, including for the enrichment of circulating tumor cells (CTCs), hematopoietic stem cells, and circulating fetal cells from blood. Current molecular analysis, while increasing biological understanding of cancer and other diseases at the DNA level, often assesses “averaged” cellular populations—derived from millions of cells across a tumor population—rather than individual cells. But, scientists believe that hard-to-detect low-level “subclones” are really the drivers of relapse or disease progression. A review of single-cell genomics in cancer, published in the Oct. 15, 2015 issue of Human Molecular Genetics, explains that ~1,000X sequencing (which is “way beyond” the depth seen in most studies) would be required to detect 99 percent of mutations carried by a one percent tumor-mass subclone analyzed at the bulk level, whereas with single-cell analysis only ~200 cells are required to reliably detect one percent tumor-mass clones. “While bulk tissue genomic analysis across large populations of tumor cells has provided key insights into cancer biology, this approach does not provide the resolution that is critical for understanding the interaction between different genetic events within the cellular hierarchy of the tumor during disease initiation, evolution, relapse, and metastasis,” writes Quin […]